New drugs: dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate.

Hussar, Daniel A; Zimmerman, David E

Hussar, Daniel A; Zimmerman, David E.

Affiliation

Hussar DA; Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA, USA.

J Am Pharm Assoc (2003) ; 51(1): 122-6, 2011.

Article in En | MEDLINE | ID: mdl-21247838

Subject(s)

Anticoagulants/therapeutic use; Benzimidazoles/therapeutic use; Contraceptives, Postcoital, Synthetic/therapeutic use; Multiple Sclerosis, Relapsing-Remitting/drug therapy; Norpregnadienes/therapeutic use; Propylene Glycols/therapeutic use; Pyridines/therapeutic use; Sphingosine/analogs & derivatives; Anticoagulants/adverse effects; Anticoagulants/pharmacology; Benzimidazoles/adverse effects; Benzimidazoles/pharmacology; Contraceptives, Postcoital, Synthetic/adverse effects; Dabigatran; Female; Fingolimod Hydrochloride; Humans; Male; Norpregnadienes/adverse effects; Propylene Glycols/adverse effects; Propylene Glycols/pharmacology; Pyridines/adverse effects; Pyridines/pharmacology; Sphingosine/adverse effects; Sphingosine/pharmacology; Sphingosine/therapeutic use; Venous Thrombosis/drug therapy; Venous Thrombosis/prevention & control

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Propylene Glycols / Pyridines / Sphingosine / Benzimidazoles / Contraceptives, Postcoital, Synthetic / Multiple Sclerosis, Relapsing-Remitting / Anticoagulants / Norpregnadienes Limits: Female / Humans / Male Language: En Year: 2011 Type: Article

Fulltext

XML

PubMed Links

Search on Google